BofA Securities on Doximity Inc (DOCS): 'No shift from DTC, but HCP growth is accelerating'

BofA Securities analyst Allen Lutz reiterated a Buy rating and $82.00 price target on Doximity Inc (NYSE: DOCS).

The analyst comments "Yesterday, we hosted a conference call on pharma ad budgets with two industry executives, Andrew McLean, and Stuart Klein (bios below). Overall, they do not expect a material shift away from direct-to-consumer (DTC) advertising despite recent FDA scrutiny. However, datapoints shared on the call indicate healthcare provider (HCP) growth is accelerating and growing faster than DTC budgets in 2026. Their commentary suggests that HCP could also take incremental share over time as pharma derisks DTC spend and leverages improved targeting in the HCP channel. Overall, we view DOCS as well positioned to capture any upside to HCP budgets over time. Maintain Buy."

For an analyst ratings summary and ratings history on Doximity Inc click here. For more ratings news on Doximity Inc click here.

Shares of Doximity Inc closed at $44.65 yesterday.

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Rackspace Technology names Chetan Gupta as Chief AI Officer
• Sharplink to stake $200M in ETH via Lido protocol